Access to cervical cancer screening strategies that facilitate early detection of clinically relevant cervical intraepithelial neoplasia associated with HPV-16/18 allows women to seek treatment sooner and may thereby improve cancer protection.

Stratifying cancer risk via HPV-16/18 genotyping in women aged ≥30 years may be cost saving compared with cotesting with cytology and HPV testing by reducing the number of screening tests and overall screening costs.

HPV-16/18 genotyping with reflex cytology is cost effective in cervical screening and represents a beneficial alternative approach to cervical screening from both a health and economic perspective.